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of the national assessment. ConClusions: This report indicates that manufactur-
ers can expect delays in the publication of national IPTs. Furthermore, manufactur-
ers can still expect their products to be evaluated at a regional level, regardless of 
undergoing the national procedure. Regional decisions may still be taking place due 
to the prolonged time taken for the publication of these national reports.
PHP266
Trends in non-submissions in THe uK
Murphy D, Vlachaki I, Guy H
WG Access Ltd, London, UK
objeCtives: Manufacturers of products selected for NICE appraisal are able to 
choose whether or not to present submissions. Choosing not to submit results 
in termination of the appraisal, with words to this effect recorded on the NICE 
website. As the reimbursement landscape in Scotland can differ to that in England 
and Wales, a comparison was made between the SMC submission status and 
the non-submission status recorded by NICE. Methods: This study reviewed 
previous NICE appraisals and examined trends in technologies and disease areas 
where a decision to not submit to NICE was taken. Single technology apprais-
als (STAs) listed as “Terminated appraisal – non submission” on the NICE web-
site were identified, with terminated appraisals categorised by year and disease 
area. Products that did not submit were entered into the SMC website to see 
whether a submission was made to the SMC. Trends in non-submissions were 
identified. Results: A total of 189 NICE STAs were identified. Of these, twenty 
submissions were recorded as non-submissions. Two of these submissions were 
later replaced by updated technology appraisals (TA147 and TA150). The frequency 
of non-submission varied by year, with five non-submissions recorded in 2013. 
Over half of these terminated submissions were in oncology. A comparison was 
made against submissions to the SMC. Of the twenty non-submissions to NICE 
only six reviews in matching indications were identified for the SMC. Of these four 
submissions were identified as full submissions. ConClusions: The decision 
to not submit to NICE was taken in 10% of STAs identified. Of those matched on 
the SMC website, four full submissions were received by the SMC. Further analy-
sis regarding the implications on reimbursement and patient access differences 
across the UK should be undertaken.
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objeCtives: To investigate differences between therapeutic innovative criteria cur-
rently used in France and Italy and their implications for pricing and reimburse-
ment. The French (Haute Autorité de Santé, HAS) and Italian (Agenzia Italiana del 
Farmaco, AIFA) national authorities both evaluate therapeutic innovation of new 
medicines as part of their drug approval process. This comparative analysis exam-
ines criteria used to assess innovation in France (Service Médical Rendu [SMR]; 
Amélioration du Service Médical Rendu [ASMR]) and Italy. Methods: Peer-reviewed 
literature including French and Italian reports and health technology assessment 
(HTA) websites were searched for publically-available records of new drugs evalu-
ated for therapeutic innovation in France and Italy since 2010. Eighteen drugs on 
the Italian innovative drug list were compared against French SMR and ASMR rank-
ings. Results: The findings of this study show similarities between the decision-
making processes in each country. However, differences exist in the algorithms 
applied to evaluate therapeutic innovation, leading to different outcomes in each 
country. For example, in 2012 ipilimumab was classified as an ‘H’ class drug (only 
fully reimbursed in hospitals) and ranked ‘important’ for innovation in Italy. On the 
other hand, in France, ipilimumab received an ‘important’ SMR score (i.e. 65% level 
of reimbursement) but only an ASMR score ‘IV’ for innovation (minor improvement 
in actual benefit in terms of therapeutic strategy). ConClusions: France and Italy 
currently have complex systems for determining therapeutic innovation to set clini-
cal value and reimbursement rates. Inconsistencies between the countries may lead 
to disparities in access and in pricing and reimbursement of innovative medicines. 
Further clarification of the terminology used in each set of criteria is required in 
both countries. France may benefit from the implementation of a simplified new 
therapeutic index (e.g. Relative Therapeutic Index, new criteria proposed in 2012).
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objeCtives: Hospital Based Health Technology Assessment (HB-HTA) became 
increasingly relevant because of its role in ensuring the introduction of evidence-
based technologies and eventually in enhancing better outcomes for end-users. 
The organizational arrangements performed to run such activities are different 
and depend on several factors, even if some common points may be considered as 
minimal basis. The aim of this study is to identify and critically appraise existing 
different organizational models for HB-HTA. Methods: Data used in this study was 
gathered within European Project AdHopHTA, granted under the 7th Framework 
Research Programme, which is aimed at strengthening the use and impact of HTA 
in hospital settings. A semi-structured interview was developed from the adapta-
tion of the European Foundation for Quality Management Model, in order to inquire 
several aspects characterizing the organizational model. Finally, 7 HB-HTA units 
were involved in the study. Results: Our results show that the organizational 
models depend on a number of contingent variables. Specifically, the combination 
of the level of formalization/specialization and the degree of integration with the 
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objeCtives: In France, decree n°2012-1116 passed on 2 October 2012 made it man-
datory for manufacturers of medicines to submit a cost-effectiveness model to the 
Economic and Public Health Assessment Committee (CEESP) when requesting an 
Improvement of Medical Benefit (ASMR) of I-III in their reimbursement submission 
to the Transparency Committee (CT). Our objective was to gauge the impact of this 
decree on the ASMR levels requested by manufacturers. Methods: We investi-
gated ASMR I-III levels requested before and after the adoption of the decree. All 
CT meeting minutes published by the French National Authority for Health (HAS) 
between January 2012 and March 2015 were reviewed. Four time periods were evalu-
ated: 1. 04/01/2015 – 03/10/2012; 2. 04/10/2012 – 03/10/2013 (the day it took effect); 3. 
04/10/2013 – 01/10/2014; 4. 02/10/2014 – 18/03/2015. Additionally we looked at initial 
submissions for new medicines, assuming these were more susceptible to be influ-
enced by the new decree. If manufacturers increased the number of requests made 
for ASMR I-III in period two and then subsequently decreased them, this would 
suggest they were trying to avoid submitting cost-effectiveness models. Results: 
Over the study period there were 231 ASMR requests of which 83 (35.9%) were for an 
ASMR I-III and 135 (58.4%) for an ASMR IV or V. The proportion of ASMR I-III requests 
for periods one, two, three and four were 19 (40.4%), 16 (27.1%), 29 (35.4%) and 19 
(44.2%) respectively. Of the 83 ASMR I-III requests 47 were initial submissions: 12 
(35.3%) period one; six (18.2%) period two; 17 (35.4%) period three; 12 (52.2%) period 
four. ConClusions: Against the baseline period, total requests for an ASMR I-III 
fell from 40.4% to 27.1% of all requested ASMRs, only to increase in each of the sub-
sequent two periods. A similar pattern holds for initial submissions. These results 
suggest manufacturers didn’t change their behaviour to avoid submitting cost-
effectiveness models.
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objeCtives: The health technology assessment (HTA) is used, among other func-
tions, in order to support decision-making on the incorporation of new technologies 
in public health systems. Generally, those decisions are based on criteria such as 
efficacy, effectiveness, safety and cost-effectiveness and, besides that the health 
system context as a whole has also a great influence on reimbursement/invest-
ment on health technologies and such informations are not always explicit or well 
weighted in a systematic way. Thus, this work aims to raise and compare system-
atic HTA tools and its criteria used during the decision-making process on new 
technologies incorporations in different health systems. Methods: A review was 
conducted, then studies describing systematic methods of HTA on reimbursement/
investment decision-making in public health system were selected and finally a 
descriptive analysis was performed. Results: As HTA systematic tools there were 
found multicriteria decision analysis (MCDA), assessment scoring system and public 
health benefit of medicines (PHB), among others. In addition to efficacy, effective-
ness, safety and cost-effectiveness criteria, some evaluations had also considered 
other elements, namely: epidemiology, disease burden, quality-adjusted life year 
(Qaly), presence of therapeutic alternative, societal value, patient impact, quality of 
the evidence, innovativeness, impacts on equity, ethical consequences, convenience, 
feasibility and acceptability. A major barrier found in multicriteria evaluation was 
the lack of reliable data for all criteria. ConClusions: This study has raised HTA 
experiences in a variety of public systems proving that HTA normally takes multic-
riteria into account. However not all of them are considered multicriteria analysis 
(MCA) because this technique generally supply an explicit relative weighting system 
for the different criteria and not all HTA proceed in this manner. Generally, it was 
noted that the use of multicriteria can contribute to objectiveness, transparency and 
accountability of the process, thus enhancing legitimacy of the political decisions.
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objeCtives: In December 2012, the Spanish Government approved publication 
of the Spanish ‘Place in Therapy’ reports (IPTs [Informes de posicionamiento tera-
péutico]) which are used to inform pricing and reimbursement decisions with the 
Ministry of Health. These reports were implemented to create a single national 
assessment and thereby negate the need for regional decision making, and ensur-
ing equal access to therapies throughout Spain. A further aim of IPTs was to ensure 
fast access, with the Spanish Government committing to their publication within 
3 months of European Medicines Agency (EMA) approval. This analysis aimed to 
determine whether IPTs have successfully met their objectives. Can manufacturers 
expect IPT publication within 3 months post-EMA approval and have they success-
fully prevented regional assessments, thereby ensuring equal access throughout 
Spain? Methods: A retrospective analysis of IPTs from their implementation 
in 2012 to present was carried out by extracting information from the Spanish 
Medicines Agency, from the EMA and from the regional health technology assess-
ment boards. Results: To June 2015, 38 drugs have been assessed via an IPT, two 
of which were assessed for more than one indication. The average time from EMA 
authorisation to IPT publication is 25 months. This is reduced to 14 months when 
only drugs marketed after December 2012 are considered. Seventy percent of the 
drugs evaluated via the IPT procedure have also been evaluated via a regional 
assessment, of which, 68% were evaluated at a regional level prior to the publication 
